Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Accounts Payables (2016 - 2025)

Vistagen Therapeutics' Accounts Payables history spans 12 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 23.2% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 23.2%, while the annual FY2025 figure was $653000.0, 57.79% down from the prior year.
  • Accounts Payables for Q4 2025 was $1.3 million at Vistagen Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.7 million in Q3 2021 and bottomed at $1800.0 in Q4 2021.
  • The 4-year median for Accounts Payables is $1.3 million (2025), against an average of $1.3 million.
  • The largest YoY upside for Accounts Payables was 20358.46% in 2021 against a maximum downside of 91.0% in 2021.
  • A 4-year view of Accounts Payables shows it stood at $1800.0 in 2021, then skyrocketed by 96400.0% to $1.7 million in 2023, then crashed by 40.18% to $1.0 million in 2024, then increased by 23.2% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Accounts Payables are $1.3 million (Q4 2025), $1.8 million (Q3 2025), and $486000.0 (Q2 2025).